carbostyril has been researched along with Schizophrenia in 581 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.17) | 18.7374 |
1990's | 2 (0.34) | 18.2507 |
2000's | 273 (46.99) | 29.6817 |
2010's | 275 (47.33) | 24.3611 |
2020's | 30 (5.16) | 2.80 |
Authors | Studies |
---|---|
Hibino, H; Inoue, Y; Matsumoto, H; Mikami, K; Suzuki, H; Takaya, A; Yamamoto, K | 2 |
Fernando, R; Gan, L; Xiao, J; Yun, Y | 1 |
Baymeeva, NV; Kaleda, VG; Miroshnichenko, II; Platova, AI; Tikhonov, DV | 1 |
Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z | 1 |
Schooler, NR | 1 |
Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U | 1 |
Hishimoto, A; Matsukawa, M; Sekine, D; Yamada, S; Yasui-Furukori, N | 1 |
Dorozhenok, IY | 1 |
Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
Harada, T; Hosokawa, T; Kishi, Y; Miyaji, C; Nomura, A; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Washida, K; Yada, Y; Yamada, N; Yoshimura, Y | 1 |
Cahill, D; Kohegyi, E; Larsen, F; Raoufinia, A; Wang, X; Wang, Y; Ward, C; Zoubroulis, A | 1 |
Cheng, CS; Kuo, CJ; Lin, SK | 1 |
Dean, B; Gogos, A; Hopper, S; Pavey, GM | 1 |
Kumakura, J; Okada, T; Suda, S; Yasuda, M | 1 |
Futamura, T; Kikuchi, T; Maeda, K; Niidome, K; Suzuki, M; Usami, T | 1 |
Aoki, S; Shimizu, H; Takeda, T; Washida, K; Yamashita, R; Yoshimura, Y | 1 |
Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K | 1 |
Antoun Reyad, A; Girgis, E; Mishriky, R | 1 |
Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D | 1 |
Ishigooka, J; Iwashita, S; Kojima, Y; Matsuo, S; Usami, T | 1 |
Baker, RA; Cox, K; Eramo, A; Kojima, Y; Okame, T; Potkin, SG; van Erp, TG | 1 |
Markovic, M; Maroney, M; Stummer, L | 1 |
Ismail, Z; Meade, N; Meehan, SR; Shi, L; Weiss, C | 1 |
Boku, S; Fujiyama, H; Fukuhara, R; Kanno, T; Kawahara, K; Sugawara, H; Takebayashi, M; Tanaka, H | 1 |
Kikuchi, T; Otsubo, T; Watanabe, Y; Yamada, S | 1 |
Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S | 1 |
Baas, CAJ; Knegtering, H; Spoelstra, SK | 1 |
Edinoff, AN; Girma, B; Kaye, AD; Kaye, AJ; Kaye, AM; Kaye, JS; Leethy, KN; Maxey, BS; Mychaskiw, G; Odisho, A; Ren, AL; Urits, I; Viswanath, O; Wu, NW | 1 |
Bruno, CD; Chow, CR; Elmokadem, A; Greenblatt, DJ; Housand, C; Jordie, EB; Lesko, LJ | 1 |
Higashi, K; Ishigooka, J; Iwashita, S; Liew, EL; Tadori, Y | 1 |
Ekinci, A; Ekinci, O | 1 |
Castle, D; Hope, J; Keks, NA | 1 |
Forbes, A; Hakala, M; Hobart, M; Ouyang, J; Pfister, S; Shi, L | 1 |
Ishigooka, J; Iwashita, S; Tadori, Y | 2 |
Goldnik, A; Mach, A; Malek, G; Marszalek, D; Pawinski, T; Somogi, A | 1 |
Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
Eriksson, H; Newcomer, JW; Weiller, E; Weiss, C; Zhang, P | 1 |
Baker, RA; Correll, CU; Duffy, RA; Eramo, A; Hobart, M; Shi, L; Weiller, E; Weiss, C | 1 |
Frampton, JE | 1 |
Limandri, BJ | 1 |
Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Valdizan, EM; Vazquez-Barquero, JL | 1 |
Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y | 1 |
El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R | 1 |
Wang, YC | 1 |
Li, W; Lv, L; Wang, S; Wang, X; Yang, G; Yang, Y; Zhang, H; Zhao, J | 2 |
Caccia, F; Caloro, M; Cuomo, I; De Filippis, S; De Persis, S; Gentile, G; Girardi, P; Janiri, D; Kotzalidis, GD; Lionetto, L; Piazzi, G; Sciarretta, A; Simmaco, M; Simonetti, A; Telesforo, CL | 1 |
Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R | 1 |
Falkai, P; Schmitt, A | 1 |
Aggarwal, A; Gopalakrishna, G; Lauriello, J | 1 |
Baker, RA; Duca, AR; Eramo, A; Johnson, BR; Kane, JM; McQuade, RD; Peters-Strickland, T; Sanchez, R; Zhao, J | 1 |
An, SK; Chang, JG; Cho, HS; Jung, YC; Kim, CH; Roh, D | 1 |
Tadokoro, S | 1 |
Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP | 1 |
Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
Remington, G; Takeuchi, H | 1 |
Tsukarzi, EE | 1 |
Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M | 1 |
Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M | 1 |
Jalenques, I; Kernisant, M; Legrand, G; May, R; Richard, B | 1 |
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB | 1 |
Carson, W; Correll, CU; Forbes, RA; Mankoski, R; Marcus, R; McQuade, R; Zhao, J | 1 |
Baker, RA; Bricmont, P; Eramo, A; Kasper, W; Mallikaarjun, S; McQuade, R; Peters-Strickland, T; Potkin, SG; Raoufinia, A; Sanchez, R | 1 |
Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R | 1 |
Hashiguchi, M; Kunitomi, T; Mochizuki, M | 1 |
Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ | 1 |
Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T | 1 |
Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD | 1 |
Poncin, YB; Stubbe, DE; Webb, JE; Webb, JR | 1 |
Arnoldy, R; Curtis, J; Samaras, K | 1 |
Au, RW; Chiu, HF; Dickerson, F; Kreyenbuhl, J; Lai, KY; Man, D; Shum, D; Tang, WK; Ungvari, GS; Wang, CY; Xiang, YT; Yu, X; Zhou, FC; Zhou, JJ; Zhou, Y | 1 |
Allain-Veyrac, G; Gaboriau, L; Gérardin, M; Grall-Bronnec, M; Jolliet-Evin, P; Victorri-Vigneau, C | 1 |
Buchanan, RW; Newcomer, JW; Weiden, PJ | 1 |
Bojarski, AJ; Marciniec, K; Partyka, A; Pawlowski, M; Wesolowska, A; Zajdel, P | 1 |
El-Sayeh, HG; Khanna, P; Komossa, K; Leucht, S; Ma, H; Rummel-Kluge, C; Suo, T; Xia, J | 1 |
Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ | 1 |
Charpeaud, T; Llorca, PM; Samalin, L | 1 |
Dai, G; Zhang, Y | 1 |
Anzai, N; Furukawa, S; Hatsuse, N; Ikebuchi, E; Iwata, K; Kishimoto, T; Matsuda, Y; Sato, S; Watanabe, Y | 1 |
Chen, TT; Huang, WL; Tsai, CH | 1 |
Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K | 1 |
Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 4 |
Sumiyoshi, T | 1 |
Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M | 1 |
Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C | 1 |
Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
Danilov, DS | 1 |
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Walling, D | 1 |
Perry, CM; Shirley, M | 1 |
Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W | 1 |
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K | 1 |
Pawelczyk, A; Pawelczyk, T; Rabe-Jablonska, J | 1 |
Gentile, S | 1 |
Baker, RA; Carson, WH; Eramo, A; Gara, M; Hertel, P; Jin, N; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R | 1 |
Goyal, P; Kumar, D; Prakash, O; Tripathi, P | 1 |
Lai, EC; Yang, YH | 1 |
Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R | 1 |
Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M | 1 |
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Tsai, LF | 1 |
Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR | 1 |
Stroup, TS | 1 |
Heres, S | 1 |
Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP | 1 |
Kobayashi, H; Tadori, Y | 1 |
Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B | 1 |
Baker, RA; Eramo, A; Kostic, D; Landsberg, W; Larsen, F; Nylander, AG; Raoufinia, A | 1 |
Gupta, SK; Kamboj, A | 1 |
Fleischhacker, WW; Sanchez, R | 1 |
Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G | 1 |
Carson, WH; Eriksson, H; Hobart, M; Kane, JM; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Skuban, A | 1 |
Audo, I; Faure, C; Letessier, JB; Robert, MP; Zeitz, C | 1 |
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK | 1 |
Howland, RH | 1 |
Carson, WH; Correll, CU; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Skuban, A | 1 |
Citrome, L | 5 |
Kibble, A | 1 |
Greig, SL | 1 |
Goff, DC | 2 |
Yee, A | 1 |
Citrome, L; McEvoy, J | 1 |
Stahl, SM | 2 |
Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E | 1 |
Garnock-Jones, KP | 1 |
Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V | 1 |
Correll, CU; Hobart, M; Kane, JM; Ouyang, J; Skuban, A; Weiller, E; Weiss, C | 2 |
Bruijnzeel, D; Tandon, R | 1 |
Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y | 1 |
Carson, WH; Fleischhacker, WW; Forbes, A; Hobart, M; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Weiller, E | 1 |
Baker, RA; Malla, A; Nagamizu, K; Ota, A; Perry, P; Weiller, E | 1 |
Hakala, MJ; Hobart, M; Josiassen, MK; Marder, SR; Ouyang, J; Weiller, E; Weiss, C; Zhang, P | 1 |
Hsu, WY; Lane, HY; Lin, CH | 1 |
Gallipani, A; Markovic, M; Maroney, M; Patel, KH | 1 |
Dhamija, R; Verma, R | 1 |
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
Abbasian, C; Power, P | 1 |
Sikich, L | 1 |
Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM | 1 |
Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A | 1 |
Collins, J; Mervak, B; Valenstein, M | 1 |
Labrie, V; Lipina, T; Roder, JC | 1 |
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M | 1 |
Nahata, T; Saini, TR | 1 |
Boulton, DW; Carson, WH; Findling, RL; Forbes, RA; Kauffman, RE; Mallikaarjun, S; Nyilas, M; Pikalov, A; Sallee, FR; Shoaf, SE | 1 |
Bachmann, CJ; Heinzel-Gutenbrunner, M; Hiemke, C; Remschmidt, H; Rieger-Gies, A; Theisen, FM | 1 |
Bhattacharjee, J; El-Sayeh, HG | 2 |
Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV | 1 |
Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P | 1 |
Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W | 1 |
Wang, SJ; Yang, TT | 1 |
Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A | 1 |
Arsura, E; Sethi, NK; Torgovnick, J | 1 |
Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS | 1 |
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R | 1 |
Kashima, H; Kikuchi, T; Manki, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 1 |
Langosch, JM; Schlachetzki, JC | 1 |
Azzoni, A; Raja, M | 1 |
Montero, I; Ruiz, I; Talavera, M | 1 |
Chen, CH; Lu, ML; Shen, WW | 1 |
Chen, CH; Chen, SF; Chen, SJ; Chen, YJ; Lin, CC; Luu, SU; Shen, YC | 1 |
Baardewijk, Mv; Davies, A; L'italien, GJ; Loze, JY; Sennfalt, K; Vardeva, K | 1 |
Baker, RA; Carson, WH; Crandall, DT; Eudicone, JM; L'italien, G; Marcus, RN; McQuade, RD; Meyer, JM; Newcomer, JW; Pikalov, A; Vester-Blokland, E | 1 |
Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R | 1 |
Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL | 1 |
Glick, ID; Ivanova, O; Koran, LM; Poyurovsky, M | 1 |
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M | 1 |
Hauser, D; Ladds, B; Mejia, C; Thomas, P | 1 |
Jong-Yih, L | 1 |
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD | 1 |
Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR | 1 |
Costentin, J | 2 |
Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M | 1 |
Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M | 1 |
Caykoylu, A; Ekinci, O; Yilmaz, E | 1 |
Chen, CH; Chen, SF; Shen, YC | 2 |
Breier, A; Kane, JM; Kryzhanovskaya, LA; Osuntokun, O; Stauffer, VL; Watson, SB; Xu, W | 1 |
Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V | 1 |
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
Chiesa, A; De Ronchi, D; Mandelli, L; Pae, CU; Serretti, A | 2 |
Bopp, K; Petti, TA; Stern, RG; Tobia, A | 1 |
Chiesa, A; De Ronchi, D; Kim, J; Lee, C; Mandelli, L; Pae, CU; Paik, IH; Serretti, A | 1 |
Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S | 1 |
Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS | 1 |
Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C | 1 |
Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A | 1 |
Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI | 1 |
Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R | 1 |
Pae, CU | 1 |
Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B | 1 |
Bachmann, CJ; Lehr, D; Preiss, M; Theisen, FM | 1 |
Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 2 |
Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY | 1 |
Mace, S; Taylor, D | 1 |
Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Suzuki, T | 1 |
Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R | 1 |
de Haan, L; Peters, B | 1 |
Shan, JC; Tseng, MC | 1 |
Pesek, MB | 1 |
El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
Gagliano, A; Masi, G | 1 |
Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E | 1 |
Fekete, S; Herold, R; Kovacs, A; Osvath, P; Simon, M; Tenyi, T; Voros, V | 1 |
Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV | 1 |
Rocha, FF | 1 |
Stip, E; Tourjman, V | 1 |
Chiesa, A; Gibiino, S; Mandelli, L; Pae, CU; Patkar, AA; Serretti, A | 1 |
Ali, M; Assunção-Talbott, S; Carson, WH; Forbes, RA; Iwamoto, T; Nyilas, M; Pikalov, A; Robb, AS; Whitehead, R | 1 |
Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T | 1 |
Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M | 1 |
Roxanas, MG | 1 |
Hanatani, T; Ikejiri, Y; Kondo, M; Sumi, N | 1 |
Beck, A; Dembler, T; Dinges, M; Friedel, E; Gallinat, J; Heinz, A; Juckel, G; Sarkar, R; Schlagenhauf, F; Wrase, J; Wüstenberg, T | 1 |
Chen, HK; Shao, CH; Wu, BJ | 1 |
Ebrecht, M; Kungel, M; Messer, T; Modell, S; Schmauss, M; Spevakne-Goeroecs, T; Werner, C | 1 |
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C | 1 |
Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
Radics, J | 1 |
Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
Cerovecki, A; Dehning, S; Engel, RR; Matz, J; Möller, HJ; Müller, N; Musil, R; Obermeier, M; Opgen-Rhein, M; Riedel, M; Schennach-Wolff, R; Seemüller, F; Severus, E; Spellmann, I | 1 |
Carrick, T; Feenstra, R; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; Pausch, MH; Reinders, JH; Robichaud, AJ; Rotella, DP; van der Neut, M; Yan, Y; Zhang, J; Zhou, P | 1 |
Deng, C; Huang, XF; Lian, J; Pai, N | 1 |
Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW | 1 |
Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP | 1 |
Chiesa, A; Pae, CU; Serretti, A | 1 |
Inada, K; Ishigooka, J; Oshibuchi, H | 1 |
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
Arand, J; Farger, G; Hiemke, C; Lutz, UC; Wiatr, G; Wildgruber, D | 1 |
Guirguis-Blake, J | 1 |
Hamidin, A; Normala, I | 1 |
Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD | 1 |
Kozumplik, O; Sedić, B; Uzun, S | 1 |
Cohen, J; Gavaudan, G; Lançon, C; Léonetti, G; Magalon, D; Pélissier-Alicot, AL | 1 |
Kibbey, KJ; Nicholson, GC; Roberts, AM | 1 |
Chen, J; Deng, C; Hu, C; Huang, XF | 1 |
Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 2 |
Brunetti, L; Patel, MK | 1 |
Chang, CC; Chen, SH; Hwang, PL; Ko, JY; Wei, SY; Yeh, HH | 1 |
Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N | 1 |
Chiesa, A; Mandelli, L; Pae, CU; Serretti, A | 1 |
Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y | 1 |
Hori, H; Nakamura, J; Okamoto, T; Umene-Nakano, W; Yoshimura, R | 1 |
Janicak, PG; Rado, J | 1 |
Kirino, E | 2 |
Carson, W; Cziraky, MJ; Delorenze, G; Niemcryk, SJ; Oliveria, SA; Phillips, S; Quesenberry, CP; Skovron, ML; Tsai, AL; Ulcickas Yood, M; Wells, K; Willey, VJ | 1 |
Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M | 1 |
Atallah, AN; Melnik, T; Puga, ME; Soares, BG | 1 |
Gen, K; Inoue, Y; Suzuki, H | 1 |
Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R | 1 |
Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F | 1 |
Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
Bastiampillai, T; Lander, M | 1 |
Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL | 1 |
Ascher-Svanum, H; Faries, DE; Kane, JM; Osuntokun, OO; Peng, X; Stauffer, VL; Stensland, MD | 1 |
Correll, CU | 1 |
Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T; Uno, T | 1 |
Lee, J; Ng, KW; Swapna, V | 1 |
Kan, HJ; King, D; Knapp, M; Loze, JY; Razzouk, D; Thomas, P; van Baardewijk, M | 1 |
Arends, J; Cohen, D; van Kooten, M | 1 |
Boyer, L; Christophe, L; Cohen, J; Magalon, D; Simon, N | 1 |
Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
Bruno, A; Di Nardo, F; Micò, U; Muscatello, MR; Pandolfo, G; Santoro, V; Scimeca, G; Spina, E; Zoccali, RA | 1 |
Chen, CY; Lin, TY; Shuai, HA; Wang, CC | 1 |
Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M | 1 |
Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S | 1 |
Hackett, LP; Ilett, K; Nguyen, T; Teoh, S | 1 |
Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E | 1 |
De Risio, A; Gentile, B; Giannarelli, D; Pancheri, A; Simonetti, G; Stefanutto, L | 1 |
Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M | 1 |
Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A | 1 |
Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY | 1 |
Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Yu, KS | 1 |
Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
Kasahara, M; Murashima, A; Nakajima, K; Nakamura, T; Sugibayashi, R; Watanabe, N; Watanabe, O | 1 |
Chiu, NY; Hsu, WY; Lee, BS; Liao, YC; Lin, TW | 1 |
Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M | 1 |
Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K | 1 |
Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N | 1 |
Sokolski, KN | 1 |
Hou, YC; Lai, CH | 1 |
Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
Bous, J; de Boer, MK; Hamamura, T; Knegtering, H; Sytema, S; van der Moolen, AE; Wiersma, D; Wilffert, B | 1 |
Fukui, N; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C | 1 |
Bowden-Jones, H; Kitchenham, N; Smith, N | 1 |
de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A | 1 |
Biswas, J; Gandhi, RA; George, RJ; Nair, AG | 1 |
Belgamwar, RB; El-Sayeh, HG | 2 |
Chou, J; Chung, MT; Lin, CH; Ma, H | 1 |
Camacho, LR; Celso, F; Da Rosa, KM; Da Silva, TG; Dos Santos, Bde J; Freitas, TM; Monteiro, JD; Pereira, P; Picada, JN; Pontes, VM; Vieira, LR | 1 |
Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
Weiden, PJ | 1 |
Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK | 1 |
Bervoets, C; Constant, E; de Patoul, A; Delatte, B; Gillain, B; Halkin, V; Kok, F; Loze, JY; Peuskens, J; Touquet, G; Vansteelandt, K | 1 |
Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
Lai, CH | 1 |
Chang, KY; Wu, YF | 1 |
Bastiampillai, T; Dhillon, R; Goh, T | 1 |
Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T | 1 |
Fleischhacker, WW; Han, C; Lee, SJ; Masand, PS; Pae, CU; Park, MH; Patkar, AA | 1 |
Chen, CK; Lin, SK; Liu, YL | 1 |
Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y | 1 |
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q | 1 |
Brotzge, K; El-Mallakh, RS; Manshadi, M | 1 |
Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R | 1 |
Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
Croxtall, JD | 1 |
Goto, S; Terao, T; Tomita, M; Uchimura, N | 1 |
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
Jindal, KC; Munjal, V; Singh, GP | 1 |
Ahlbrand, R; Bronson, SL; Grainger, M; Horn, P; McNamara, RK; Richtand, NM; Tambyraja, R | 1 |
Hashimoto, N; Ito, K; Koyama, T; Kusumi, I; Matsuda, N | 1 |
Doey, T | 1 |
Han, C; Jeong, HG; Joe, SH; Ko, YH; Lee, HY; Lee, MS | 1 |
Johnsen, E; Kroken, RA | 1 |
Chang, LR; Huang, WL | 1 |
Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
Dunn, G; French, P; Hutton, P; Morrison, AP; Taylor, PJ; Yung, AR | 1 |
Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P | 1 |
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D | 1 |
Kikuchi, T; Tadori, Y | 1 |
Carson, WH; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Sanchez, R | 1 |
Abdallah, CG; Hong, X; Huang, H; Huang, Q; Jiang, L; Liang, C; Liu, Y; Wan, X; Wang, J; Wu, R; Xu, C; Zhang, J | 1 |
Fleischhacker, WW; Uchida, H | 1 |
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB | 1 |
Alvir, JM; Berger, A; Edelsberg, J; Mychaskiw, MA; Oster, G; Sanders, KN | 1 |
Moteshafi, H; Stip, E | 1 |
Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K | 1 |
Borba, CP; Copeland, P; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC | 1 |
Chaumartin, N; Lachaux, B; Monville, M | 1 |
Bervoets, C; Constant, E; de Patoul, A; Halkin, V; Kok, F; Morrens, M; Peuskens, J; Pitsi, D; Sabbe, B; Vansteelandt, K | 1 |
Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M | 1 |
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T | 1 |
Landowski, J; Wichowicz, H; Wilkowska, A | 1 |
Hiranyatheb, T; Ittasakul, P; Ketter, TA; Srivastava, S | 1 |
Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
Chang, HC; Chang, LR; Huang, WL; Liu, CM; Tsai, YF | 1 |
Bouvard, S; Ciumas, C; d'Amato, T; Daléry, J; Lerond, J; Lothe, A; Poulet, E; Ryvlin, P; Saoud, M | 1 |
Chen, L; Zhou, Z; Zhu, H | 1 |
Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D | 1 |
Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W | 1 |
Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S | 1 |
Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M | 1 |
Leung, JG; Nelson, S | 1 |
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
Goa, KL; McGavin, JK | 1 |
Goodnick, PJ; Jerry, JM | 1 |
Ali, MW; Carson, WH; Casey, DE; Ingenito, GG; Jody, D; Liebeskind, A; Saha, AR | 1 |
Bailey, KP | 1 |
Keck, PE; McElroy, SL | 1 |
Buckley, PF | 2 |
Bowles, TM; Levin, GM | 1 |
Crismon, ML; DeLeon, A; Miller, AL | 1 |
Kutscher, EC | 1 |
Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E | 1 |
Gasperoni, TL; Grady, MA; Kirkpatrick, P | 1 |
Woods, SW | 1 |
Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J | 1 |
Carlsson, A; Grunder, G; Wong, DF | 1 |
Kaplan, D; Koliatsos, V; Lindsey, RL; Sandson, NB; Walters, JK | 1 |
Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A | 1 |
Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF | 1 |
Tamminga, CA | 1 |
Winans, E | 1 |
Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
Buckley, PF; Glazer, W; Sebastian, CS | 1 |
DeQuardo, JR | 1 |
Green, B | 1 |
Lieberman, JA | 1 |
Duggal, HS | 1 |
El-Sayeh, HG; Morganti, C | 2 |
Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B | 1 |
Crismon, ML; DeLeon, A; Patel, NC | 1 |
Perry, CM; Swainston Harrison, T | 1 |
Kasper, S; Winkler, D | 1 |
Fear, C | 1 |
Shayegan, DK; Stahl, SM | 1 |
Chakraborty, N; Johnston, T | 1 |
Tsai, SJ | 1 |
Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H | 1 |
Lambert, M; Naber, D | 1 |
Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S | 1 |
Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE | 1 |
Bolonna, AA; Kerwin, RW | 1 |
Cousins, DA; Young, AH | 1 |
Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH | 1 |
Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
Launer, M | 1 |
Kinghorn, WA; McEvoy, JP | 1 |
Bartholomä, A; Gregor, A; Hein, J; Heinz, A; Juckel, G | 1 |
Bridler, R | 1 |
Alfers, J; Beresford, HF; Beresford, TP; Clapp, L; Martin, B; Wiberg, JL | 1 |
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
Ostroff, R; Wahl, R | 1 |
Barr, BM; Coughenour, LL; Gregory, TF; Singer, JM; Walters, MA | 1 |
Been, A; de Bruijn, C; Vergouwen, AC | 1 |
Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Saria, A; Zernig, G | 1 |
Church, CO; Fugate, SE; Stevens, DL | 1 |
Fleischhacker, WW | 1 |
Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
Hirose, T; Kikuchi, T | 1 |
Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S | 1 |
Odiyoor, M; Salmoiraghi, A | 1 |
Duggal, V; Glick, ID; Hodulik, C | 1 |
Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J | 1 |
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
Bork, B; Christensen, A; Christensen, AF; Christensen, M; Nielsen, CT; Poulsen, J | 1 |
Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R | 1 |
Raja, M | 1 |
Baciu, D; Walther, S | 1 |
Ebrecht, M; Göröcs, T; Gründer, G; Kungel, M; Modell, S | 1 |
Harms, E; Kropp, S; Luebbe, G; Ziegenbein, M | 1 |
Kantrowitz, JT; Srihari, VH; Tek, C | 2 |
Kim, YK; Lee, BH; Park, SH | 1 |
Clarke, LA; Kaushik, S; Lindenmayer, JP | 1 |
Duggal, HS; Mendhekar, DN | 1 |
Strawn, JR | 1 |
Bahta, E; Levine, S; Manas, K; Reddymasu, S; Slay, LE | 1 |
Bourin, M | 1 |
Gaszner, P | 1 |
Almond, SL; Armstrong, EJ; Brandon, NJ; Chiu, CS; Fradley, RL; Heavens, RB; Hutson, PH; Konno, R; Newman, RJ; Rutter, AR | 1 |
Tsai, JF | 1 |
Egger, C; Geretsegger, C; Muehlbacher, M; Nickel, M; Rauscher, A; Stuppaeck, C | 1 |
Adams, CE; El-Sayeh, HG; Morganti, C | 1 |
Crossman, AM; Lindenmayer, JP | 1 |
Alla, L; Sabaratnam, M; Shastri, M | 1 |
Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 3 |
Gründer, G; Paulzen, M | 1 |
Carson, WH; Cutler, AJ; Hardy, SA; Marcus, RN; McQuade, RD; O'Donnell, A | 1 |
Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E | 1 |
Fernald, DS; Hovens, JE; Loonen, AJ; van Dellen, RT | 1 |
Kang, SG; Kim, L; Lee, HJ; Lee, MS; Park, JS | 1 |
Harborne, GC; Karunakaran, K; Tungaraza, TE | 1 |
Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
Kovács, G; Kovács, L | 1 |
Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E | 1 |
Dimopoulos, NP; Kararizou, EG; Katsa, AN; Katsanou, MN; Mitropoulos, PA; Mitsonis, CI; Tsakiris, FE | 1 |
Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y | 1 |
Hirose, T; Kameya, T; Kikuchi, T; Mamiya, N; Taguchi, M; Yamada, S | 1 |
Padala, KP; Padala, PR; Sadiq, HJ | 1 |
Abu-Tair, F; Bergemann, N; Kopitz, J | 1 |
Chavez, B; Poveda, RA | 1 |
Kropp, S; Wittmann, G; Ziegenbein, M | 1 |
De Oliveira, IR; Juruena, MF | 1 |
Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A | 1 |
Liskow, BI; Moeller, KE; Shireman, TI | 1 |
Arlien-Soborg, P; Kondziella, D | 1 |
Oosterhuis, M; Tenback, D; Van De Kraats, G | 1 |
Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C | 1 |
Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK | 1 |
Pinninti, NR; Sanghadia, M | 1 |
Keller Ashton, A | 1 |
Thomas, P | 1 |
Limosin, F | 1 |
Lamberti, JS; Olsen, D; Spurling, RD; Tang, W; Tu, X | 1 |
Freeman, B; Gorman, JM; Levy, W | 1 |
Chen, YY; Hung, GC | 2 |
Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE | 1 |
Crandall, DT; Gutierrez-Esteinou, R; Lau, GS; Marcus, RN; Marder, SR; Pikalov, A; Pultz, JA; West, B | 1 |
Chen, CH; Chen, SJ; Lin, CC; Shen, YC | 1 |
Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
Fan, XW; Luo, JW; Zeng, DZ | 1 |
Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M | 1 |
Bienroth, M; Jones, M; Millar, H; Ratna, L; Sullivan, G; Taylor, D | 1 |
Feldman, JJ; Rosenberg, J; Salzman, C | 1 |
Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA | 1 |
Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD | 1 |
Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
Bourgeois, JA; Kahn, D | 1 |
Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W | 1 |
Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
Adelbrecht, C; Allain, H; Bernardo, M; Janssen, F; Laughton, J; Lublin, H; Maier, W; Millar, H; Pans, M; Salokangas, RK; Smeraldi, E; Werner, C; Wolf, J | 1 |
Wooten, J | 1 |
Kessler, RM | 1 |
Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH | 1 |
Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM | 1 |
Chiclana, C; Gonzalez, R; Lopez-Garcia, P | 1 |
Burchardt, C; Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Piel, M | 1 |
Chen, CH; Huang, MC; Lu, ML | 2 |
Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D | 1 |
Allen, MH; Nordstrom, K | 1 |
Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN | 1 |
Atkinson, J; Fischetti, C; Jones, S; Sparshatt, A; Taylor, D | 1 |
Chou, YH; Su, TP; Yang, KC | 1 |
Keating, GM; Sanford, M | 2 |
Bushe, CJ; Leonard, BE | 1 |
Rosenheck, RA | 1 |
Hettema, JM; Ross, DE | 1 |
Lee, C; Lee, CU; Lim, HK; Pae, CU | 1 |
Thone, J | 1 |
Eudicone, JM; Kim, E; Miller, DD; Pikalov, A | 1 |
Chou, SY; Chung, PC; Su, JA; Tsang, HY | 1 |
Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
Gonidakis, F; Papadimitriou, G; Ploubidis, D | 1 |
Desseilles, M; Mathot, F | 1 |
Gray, R; Jones, M | 1 |
Bashir, M; Macrae, A; Shajahan, P; Taylor, M | 1 |
Hughes, D; Morcos, M | 1 |
Hazra, M; Mamo, DC; Remington, G | 1 |
Poyurovsky, M; Weizman, A; Weizman, R | 1 |
Sanford, M; Scott, LJ | 1 |
Andersen, SE; Johansson, M; Manniche, C | 1 |
Bianchi, F; Di Lorenzo, G; Leo, R; Razzini, C; Romeo, F; Siracusano, A; Tesauro, M; Zanasi, M | 1 |
Ahn, YM; Chang, JS; Kang, UG; Kim, SH; Kim, YS; Lee, KY; Park, HJ | 1 |
Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
Boy, C; Bröcheler, A; Fellows, C; Gründer, G; Hellmann, S; Hiemke, C; Janouschek, H; Kirschbaum, KM; Rösch, F; Schaefer, WM; Spreckelmeyer, KM; Vernaleken, I; Veselinovic, T | 1 |
Abi-Dargham, A; Alvarez, B; Bae, SA; Frankle, WG; Gil, R; Gonzales, R; Hackett, E; Kegeles, LS; Kim, JH; Laruelle, M; Slifstein, M; Xu, X | 1 |
Hanssens, L; L'Italien, G; Loze, JY; Marcus, RN; Pans, M; Taylor, D | 1 |
Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD | 1 |
Campanella, LM; Lartey, R; Shih, R | 1 |
Strange, PG | 1 |
Hwang, MY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
Kelly, DL; Shim, JC; You, YS | 1 |
Bailey, P; Castro, JO; Crocq, MA; Duval, F; Lataste, X; Macher, JP; Mokrani, MC | 1 |
Cañive, JM; Davis, JT; Edgar, JC; Lewine, JD; Miller, GA; Torres, F; Tuason, VB | 1 |
Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
Fourie, J; Ozdemir, V; Ozdener, F | 1 |
Biziere, K; Bramer, S; Dannals, RF; Dogan, AS; Gründer, G; Ravert, H; Stephane, M; Suri, A; Wong, DF; Yokoi, F | 1 |
Bochnik, J; Demisch, L; Gerbaldo, H; Lehmann, CO | 1 |
121 review(s) available for carbostyril and Schizophrenia
Article | Year |
---|---|
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2020 |
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes | 2020 |
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective.
Topics: Adult; Antipsychotic Agents; Dopamine Agonists; Humans; Psychiatry; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes | 2021 |
Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
Topics: Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2018 |
Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2018 |
Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Glucose; Humans; Longitudinal Studies; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Triglycerides; Weight Gain | 2018 |
Brexpiprazole: A Review in Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Humans; Japan; Quinolones; Schizophrenia; Serotonin Receptor Agonists; Thiophenes; United States | 2019 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
Long-acting injectable aripiprazole: how might it fit in our tool box?
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States | 2013 |
[Aripiprazole as "dopamine sensitivity stabilizer"].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia | 2013 |
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2013 |
[Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Follow-Up Studies; Humans; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2013 |
Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Time Factors | 2013 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2013 |
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2013 |
Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
Topics: Antipsychotic Agents; Aripiprazole; Humans; Isoquinolines; Piperazines; Protein Binding; Quinolines; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Sulfonamides | 2014 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
Topics: Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Hostility; Humans; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2014 |
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2014 |
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia | 2014 |
[In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetulus; Depression; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Synaptic Transmission | 2014 |
Initiation of aripiprazole once-monthly in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomedical Research; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2015 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2015 |
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2015 |
Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Topics: Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes | 2015 |
Brexpiprazole (Rexulti) for schizophrenia and depression.
Topics: Animals; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin Agents; Thiophenes | 2015 |
Brexpiprazole: First Global Approval.
Topics: Depressive Disorder; Drug Approval; Humans; Internationality; Molecular Structure; Quinolones; Schizophrenia; Thiophenes | 2015 |
Brexpiprazole for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome | 2016 |
Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes | 2016 |
Brexpiprazole: A Review in Schizophrenia.
Topics: Animals; Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes | 2016 |
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
Topics: Acute Disease; Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes | 2016 |
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes | 2016 |
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
Topics: Animals; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes | 2016 |
Brexpiprazole for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Cognition; Dopamine; Humans; Psychomotor Agitation; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin; Thiophenes | 2017 |
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Brexpiprazole.
Topics: Antidepressive Agents; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Weight Gain | 2017 |
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Aripiprazole versus typical antipsychotic drugs for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sex Distribution; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol; Cholesterol, HDL; Endpoint Determination; Female; Humans; Lipoproteins; Male; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2009 |
[A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Neurons; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Synaptic Transmission | 2009 |
A review of the safety and tolerability of aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2009 |
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Design; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2009 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
[Action of amygdala dopamine and effect of antipsychotics].
Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Catecholamines; Conditioning, Classical; Dopamine; Fear; Haloperidol; Humans; Piperazines; Quinolones; Rats; Schizophrenia; Schizophrenic Psychology; Stress, Psychological | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Aripiprazole for late-life schizophrenia.
Topics: Aged; Aging; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2010 |
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Multicenter Studies as Topic; Olanzapine; Patient Selection; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Switching and combining antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2010 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
Aripiprazole versus placebo for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia | 2011 |
Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sex Characteristics; Treatment Outcome; Young Adult | 2012 |
Aripiprazole: a review of its use in the management of schizophrenia in adults.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2012 |
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Is rational antipsychotic polytherapy feasible? A selective review.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piperazines; Prolactin; Quinolones; Schizophrenia | 2012 |
Efficacy and safety of aripiprazole in child and adolescent patients.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Bipolar Disorder; Child; Humans; Piperazines; Quinolones; Schizophrenia | 2012 |
Aripiprazole vs placebo for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2012 |
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2012 |
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Topics: Antipsychotic Agents; Aripiprazole; Cells, Cultured; Colforsin; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2012 |
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Humans; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Schizophrenia | 2014 |
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Hypercholesterolemia; Incidence; Pharmacovigilance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2012 |
Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Torticollis; Young Adult | 2012 |
Aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cognition; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2002 |
Aripiprazole: profile on efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Cardiovascular System; Clinical Trials as Topic; Digestive System; Dyskinesia, Drug-Induced; Humans; Mental Disorders; Piperazines; Quinolones; Schizophrenia | 2002 |
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2003 |
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2003 |
Aripiprazole: a new atypical antipsychotic drug.
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole: quite possibly a new type of antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Prolactin; Putamen; Quinolones; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed | 2003 |
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Focus on aripiprazole.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2004 |
Dopamine partial agonists: a new class of antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome | 2004 |
Aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome | 2004 |
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome | 2004 |
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Risperidone; Schizophrenia; Time Factors | 2004 |
Partial agonism and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Brain; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2005 |
Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Mood Disorders; Piperazines; Quinolones; Schizophrenia | 2005 |
Partial dopamine agonists in schizophrenia.
Topics: Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Aripiprazole: pharmacology, efficacy, safety and tolerability.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia | 2005 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Molecular Structure; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2005 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
Aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2006 |
Aripiprazole for schizophrenia. Systematic review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Patient Compliance; Piperazines; Prolactin; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Treatment Outcome | 2006 |
[The antipsychotic drug aripiprazole (ABILIFY)].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Aripiprazole: in adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2007 |
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia | 2007 |
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Aripiprazole versus typicals for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Injections, Intramuscular; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia | 2008 |
Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Inverse Agonism; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Signal Transduction | 2008 |
Aripiprazole in adolescents with schizophrenia: profile report.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2008 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Aripiprazole (Otsuka Pharmaceutical Co).
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Dopamine Antagonists; Humans; Piperazines; Quinolones; Schizophrenia; Technology, Pharmaceutical | 2002 |
147 trial(s) available for carbostyril and Schizophrenia
Article | Year |
---|---|
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Female; Headache; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Thiophenes; Treatment Outcome; Young Adult | 2020 |
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study.
Topics: Adult; Cerebral Cortex; Dopamine Agonists; Double-Blind Method; Female; Humans; Impulsive Behavior; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Quinolones; Schizophrenia; Task Performance and Analysis; Thiophenes; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurotransmitter Agents; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Severity of Illness Index; Thiophenes | 2020 |
Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.
Topics: Antipsychotic Agents; Area Under Curve; Asian People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes | 2018 |
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Secondary Prevention; Thiophenes | 2018 |
Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Thiophenes | 2018 |
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes | 2019 |
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Intramuscular aripiprazole in the acute management of psychomotor agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Hospitals, University; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2013 |
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Incidence; Injections, Intramuscular; Maintenance Chemotherapy; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Weight Gain; Young Adult | 2013 |
Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Community Mental Health Services; Cross-Over Studies; Delayed-Action Preparations; Female; Hospitalization; Humans; Injections, Intramuscular; Male; North America; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index; Standard of Care | 2013 |
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult | 2013 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Multivariate Analysis; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2013 |
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome | 2013 |
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Piperazines; Placebos; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2013 |
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Sex Factors; Time Factors | 2013 |
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors | 2013 |
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia | 2013 |
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Remission Induction; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome | 2013 |
Predictive value of prospective memory for remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Memory, Episodic; Olanzapine; Piperazines; Prognosis; Quinolones; Remission Induction; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss | 2014 |
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult | 2014 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2014 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Obesity; Piperazines; Quinolones; Schizophrenia; Withholding Treatment | 2014 |
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain | 2014 |
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia | 2014 |
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Placebos; Quinolones; Schizophrenia; Treatment Outcome | 2014 |
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biological Availability; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2014 |
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Self Care; Social Behavior; Treatment Outcome | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
The Chinese First-Episode Schizophrenia Trial: background and study design.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Quinolones; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Young Adult | 2015 |
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Female; Humans; Lipids; Male; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome; Weight Gain | 2015 |
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain | 2016 |
[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2016 |
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult | 2017 |
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Early Diagnosis; Female; Follow-Up Studies; Humans; Male; Outpatients; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Young Adult | 2016 |
Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2017 |
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nomograms; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2017 |
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Biological Availability; Biotransformation; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2008 |
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2008 |
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult | 2008 |
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2008 |
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult | 2008 |
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia | 2009 |
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult | 2008 |
Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior; Treatment Outcome | 2008 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult | 2009 |
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Female; Genotype; Glycine; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Restriction Fragment Length; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D3; Retrospective Studies; Schizophrenia; Serine; Time Factors; Treatment Outcome | 2009 |
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptor, Serotonin, 5-HT2A; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Young Adult | 2009 |
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phobic Disorders; Piperazines; Prospective Studies; Psychometrics; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2009 |
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Combination; Government Regulation; Haloperidol; Humans; Italy; Piperazines; Prospective Studies; Quinolones; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index | 2009 |
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Health Status; Humans; Male; Middle Aged; Outpatients; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quinolones; Risperidone; Schizophrenia; Sexuality; Treatment Outcome | 2009 |
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides | 2009 |
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Failure | 2009 |
Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.
Topics: Antimanic Agents; Aripiprazole; Carbamazepine; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2009 |
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2009 |
Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2010 |
Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
Topics: Administration, Oral; Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hostility; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Syndrome; Time Factors; Treatment Outcome | 2010 |
Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Germany; Humans; Male; Nausea; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Vomiting | 2010 |
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Cognition; Humans; Inpatients; Memory; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reaction Time; Schizophrenia; Time Factors; Treatment Outcome | 2010 |
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Social Behavior Disorders; Young Adult | 2010 |
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain | 2010 |
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Residence Characteristics; Schizophrenia; Standard of Care; Surveys and Questionnaires; Treatment Outcome | 2011 |
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Double-Blind Method; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2011 |
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2011 |
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Mood Disorders; Personal Satisfaction; Pilot Projects; Piperazines; Pleasure; Quinolones; Risperidone; Schizophrenia | 2011 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors | 2011 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2012 |
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study).
Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors | 2012 |
A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2012 |
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome | 2011 |
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Topics: Acute Disease; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Female; Genetic Carrier Screening; Genotype; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taq Polymerase; Treatment Outcome; Young Adult | 2012 |
Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Young Adult | 2012 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2013 |
Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Basal Ganglia Diseases; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Japan; Male; Mass Spectrometry; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Young Adult | 2012 |
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Proportional Hazards Models; Quinolones; Schizophrenia; Secondary Prevention | 2012 |
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology | 2013 |
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2012 |
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Antipsychotic Agents; Aripiprazole; Body Composition; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose; Glucose Tolerance Test; Humans; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Piperazines; Quinolones; Schizophrenia | 2013 |
Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Memory; Middle Aged; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Semantics; Treatment Outcome; Verbal Learning; Young Adult | 2012 |
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2012 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2003 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2003 |
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2004 |
Aripiprazole in schizophrenia with cocaine dependence: a pilot study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2005 |
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Body Mass Index; Denmark; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors | 2006 |
[Clinical observations with aripiprazole in schizophrenia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Single-Blind Method; Treatment Outcome | 2006 |
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment | 2006 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Time Factors | 2007 |
Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2006 |
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
[Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Community Mental Health Services; Female; Humans; Lipoproteins; Male; Middle Aged; Patient Care; Piperazines; Prolactin; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Weight Gain | 2007 |
Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Pilot Projects; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2007 |
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).
Topics: Antipsychotic Agents; Aripiprazole; Europe; Humans; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 2007 |
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 2007 |
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss | 2007 |
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Choice Behavior; Community Mental Health Services; Consumer Behavior; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires | 2008 |
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia | 2008 |
Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Male; Neurosecretory Systems; Piperazines; Prolactin; Quinolones; Schizophrenia; Sulpiride | 1993 |
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Electroencephalography; Humans; Male; Piperazines; Quinolones; Schizophrenia | 1998 |
313 other study(ies) available for carbostyril and Schizophrenia
Article | Year |
---|---|
Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Schizophrenia; Thiophenes | 2021 |
Hyperprolactinemia induced by brexpiprazole in patients with schizophrenia: A case report.
Topics: Antipsychotic Agents; Humans; Hyperprolactinemia; Quinolones; Schizophrenia; Thiophenes | 2021 |
[Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult | 2022 |
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior | 2022 |
Functional Outcomes of an Antipsychotic Medication in Schizophrenia: A Generalizable or Specific Effect?
Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes | 2022 |
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult | 2022 |
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study.
Topics: Antipsychotic Agents; Humans; Japan; Quinolones; Retrospective Studies; Schizophrenia; Thiophenes | 2022 |
[Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Recurrence; Schizophrenia | 2022 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hospitals; Humans; Olanzapine; Patient Discharge; Piperazines; Quinolones; Retrospective Studies; Schizophrenia | 2023 |
Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Humans; Quinolones; Schizophrenia; Thiophenes | 2023 |
Brexpiprazole for the Treatment of Tics in a Patient With Schizophrenia.
Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes; Tics | 2023 |
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.
Topics: Allosteric Regulation; Autoradiography; Case-Control Studies; Cerebral Cortex; Corpus Striatum; Female; Hippocampus; Humans; Male; Middle Aged; N-Methylscopolamine; Protein Binding; Quinolones; Radioligand Assay; Receptor, Muscarinic M1; Schizophrenia; Tritium | 2019 |
Treatment-resistant schizophrenia successfully maintained with brexpiprazole following abrupt withdrawal of clozapine due to neutropenia.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Female; Humans; Neutropenia; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes | 2020 |
[Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Quinolones; Schizophrenia; Tablets; Thiophenes; Treatment Outcome | 2019 |
Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Serotonin Agents; Thiophenes; Withholding Treatment | 2020 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes | 2020 |
Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes | 2020 |
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Japan; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
[Brexpiprazole for treatment of schizophrenia: a critical literature study].
Topics: Antipsychotic Agents; Belgium; Humans; Netherlands; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Retrospective Studies; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
Topics: Antipsychotic Agents; Area Under Curve; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Genotype; Half-Life; Humans; Metabolic Clearance Rate; Models, Biological; Phenotype; Quinolones; Schizophrenia; Thiophenes | 2022 |
SIMULTANEOUS ASSAY OF ARIPIPRAZOLE AND ITS ACTIVE METABOLITE IN SERUM BY HPLC.
Topics: Acetonitriles; Activation, Metabolic; Antipsychotic Agents; Aripiprazole; Buffers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Compounding; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Phosphoric Acids; Piperazines; Quinolones; Schizophrenia; Solvents; Water | 2017 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin Antagonists; Thiophenes | 2019 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome | 2013 |
Dose-related reversible hypotension during aripiprazole treatment.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Hypotension; Male; Piperazines; Quinolones; Schizophrenia; Young Adult | 2013 |
Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia.
Topics: Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Asian People; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; DNA; Estrogen Receptor alpha; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Male; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2013 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors | 2013 |
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Biomarkers; Disease Progression; Histone Deacetylase Inhibitors; Humans; Piperazines; Quinolones; Schizophrenia | 2013 |
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Republic of Korea; Schizophrenia | 2014 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, Combination; Humans; Intestinal Obstruction; Lamotrigine; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Treatment Outcome; Triazines | 2013 |
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult | 2014 |
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quinolones; Schizophrenia | 2014 |
Aspirin as an adjunctive treatment for childhood onset schizophrenia.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aripiprazole; Aspirin; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2013 |
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss | 2014 |
Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Young Adult | 2014 |
Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia.
Topics: Aripiprazole; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2014 |
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Schizophrenia; Young Adult | 2014 |
Serotonin(1A) receptors in the action of aripiprazole.
Topics: Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Female; Humans; Male; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia | 2014 |
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride | 2014 |
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2014 |
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hypertriglyceridemia; Liver; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Transaminases; Treatment Outcome | 2014 |
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population.
Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; MicroRNAs; Phenotype; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2014 |
High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2015 |
No better solution for antipsychotic treatment with regard to long-term safety and effectiveness.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia | 2015 |
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride | 2015 |
What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2014 |
Long-acting injectable antipsychotics: an underutilized treatment option.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2014 |
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation | 2015 |
The 'unknown' safety concern for aripiprazole once monthly.
Topics: Antipsychotic Agents; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2015 |
Authors' reply.
Topics: Antipsychotic Agents; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2015 |
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Substitution; Humans; Italy; Piperazines; Quinolones; Schizophrenia | 2015 |
Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features.
Topics: Antipsychotic Agents; Aripiprazole; Coloring Agents; Dark Adaptation; Electrooculography; Electroretinography; Female; Fluorescein Angiography; Humans; Indocyanine Green; Middle Aged; Multimodal Imaging; Piperazines; Quinolones; Retina; Retinal Diseases; Retinal Pigment Epithelium; Schizophrenia; Tomography, Optical Coherence; Visual Acuity | 2015 |
Brexpiprazole: another multipurpose antipsychotic drug?
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Psychomotor Agitation; Quinolones; Schizophrenia; Stress Disorders, Post-Traumatic; Thiophenes | 2015 |
American Psychiatric Association - 168th Annual Meeting (May 16-20, 2015 - Toronto, Canada).
Topics: Alcoholism; Benzofurans; Canada; Drug Discovery; Humans; Indoles; Mental Disorders; Piperazines; Psychiatry; Quinolones; Schizophrenia; Thiophenes; Vilazodone Hydrochloride | 2015 |
Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole.
Topics: Antipsychotic Agents; Female; Humans; Male; Quinolones; Schizophrenia; Thiophenes | 2015 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia | 2016 |
Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy.
Topics: Antipsychotic Agents; Aripiprazole; Child; Diabetic Ketoacidosis; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2008 |
A case of aripiprazole and tardive dyskinesia.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult | 2009 |
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia | 2008 |
Case report of aripiprazole usage during pregnancy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Infant, Newborn; Maternal Behavior; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Quinolones; Schizophrenia; Treatment Outcome | 2008 |
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Carrier Proteins; Clozapine; Disease Models, Animal; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Tissue Proteins; Phenotype; Quinolones; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Sarcosine; Schizophrenia; Schizophrenic Psychology; Serine; Social Behavior; Space Perception | 2008 |
D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cholesterol; Delayed-Action Preparations; Lactic Acid; Microspheres; Particle Size; Piperazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Quinolones; Schizophrenia; Solubility; Solvents | 2008 |
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2008 |
Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
Topics: Adolescent; Adult; Aging; Antipsychotic Agents; Aripiprazole; Biotransformation; Body Mass Index; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quinolones; Regression Analysis; Schizophrenia; Sex Characteristics; Young Adult | 2008 |
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
Topics: Antipsychotic Agents; Aripiprazole; Corpus Striatum; Humans; Piperazines; Positron-Emission Tomography; Quality of Life; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Time Factors | 2008 |
Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Personality Disorders; Piperazines; Psychotropic Drugs; Quinolones; Retrospective Studies; Schizophrenia; Spain | 2008 |
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2008 |
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia | 2008 |
Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia.
Topics: Animals; Aripiprazole; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Male; Neuroprotective Agents; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia | 2008 |
Aripiprazole-induced orthostatic hypotension and cardiac arrhythmia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Hypotension, Orthostatic; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachycardia, Supraventricular | 2008 |
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Libido; Piperazines; Quinolones; Schizophrenia; Sexual Dysfunction, Physiological | 2008 |
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Genetic Predisposition to Disease; Hospitalization; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taiwan; Treatment Outcome; Young Adult | 2009 |
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Decision Support Techniques; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Olanzapine; Patient Acceptance of Health Care; Piperazines; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; United Kingdom | 2008 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Risperidone; Schizophrenia; Valproic Acid | 2009 |
Successful switch from clozapine to aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Administration Schedule; Drug Resistance; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2009 |
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia | 2009 |
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Influence of TAAR6 polymorphisms on response to aripiprazole.
Topics: Adult; Aripiprazole; Cell Cycle Proteins; Female; Genetic Linkage; Genetic Markers; Haplotypes; Humans; Male; Middle Aged; Nuclear Proteins; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Quinolones; Receptors, G-Protein-Coupled; Schizophrenia | 2009 |
Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study.
Topics: Antipsychotic Agents; Aripiprazole; Germany; Health Status Indicators; Humans; Physicians' Offices; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychology; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2009 |
Aripiprazole in treatment-refractory schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Consciousness Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Hospitalization; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia | 2009 |
Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia | 2009 |
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Young Adult | 2009 |
Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Syndrome; Treatment Outcome | 2009 |
Therapy and quality of life of patients with psychosis.
Topics: Adult; Animal Assisted Therapy; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Family Therapy; Humans; Male; Object Attachment; Piperazines; Psychotherapy; Psychotherapy, Group; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Environment | 2009 |
Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium.
Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Female; Humans; Lithium Carbonate; Neutropenia; Piperazines; Quinolones; Schizophrenia | 2009 |
No influence of FAT polymorphisms in response to aripiprazole.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cadherins; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2010 |
Effectiveness of intramuscular aripiprazole injection in patients with catatonia: report on three cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides | 2010 |
Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Approval; Europe; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
[Aripiprazole-induced stuttering treated with risperidone].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia; Stuttering | 2009 |
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Blinking; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention | 2010 |
Pathological gambling and compulsive eating associated with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Eating; Female; Gambling; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D3; Schizophrenia; Weight Gain | 2010 |
[Disappearance of paroxysmal perceptual alteration by switching to aripiprazole in a schizophrenic patient].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Perceptual Distortion; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain Mapping; Chlorpromazine; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Piperazines; Quinolones; Reaction Time; Schizophrenia; Schizophrenic Psychology; Time Factors; Visual Cortex; Young Adult | 2010 |
Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2010 |
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Female; Homovanillic Acid; Humans; Longitudinal Studies; Male; Methoxyhydroxyphenylglycol; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Young Adult | 2010 |
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Treatment Failure; Young Adult | 2010 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2010 |
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia | 2010 |
Trial of aripiprazole in the treatment of first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Carrier Proteins; Female; Humans; Intracellular Signaling Peptides and Proteins; Korea; Male; Neuropsychological Tests; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2010 |
Aripiprazole in pregnancy and lactation: a case report.
Topics: Adult; Aripiprazole; Breast Feeding; Female; Humans; Infant, Newborn; Lactation; Male; Milk, Human; Piperazines; Pregnancy; Quinolones; Schizophrenia | 2010 |
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia | 2010 |
The use of aripiprazole in early onset schizophrenia: safety and efficacy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss | 2010 |
Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Crime; Forensic Psychiatry; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Violence | 2010 |
Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia | 2010 |
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2010 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2010 |
Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia.
Topics: Adult; Amlodipine; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Electrophoresis, Capillary; Female; Humans; Hydrogen-Ion Concentration; Male; Piperazines; Quinolones; Reference Values; Schizophrenia; Solvents | 2010 |
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
No influence of DTNBP1 polymorphisms on the response to aripiprazole.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Dysbindin; Dystrophin-Associated Proteins; Female; Haplotypes; Humans; Linkage Disequilibrium; Male; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia | 2010 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 2011 |
A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Meige Syndrome; Piperazines; Quinolones; Schizophrenia; Thiazoles; Young Adult | 2011 |
Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Japan; Male; Piperazines; Quinolones; Schizophrenia; Stupor; Treatment Outcome | 2010 |
Epidemiologic study of aripiprazole use and the incidence of suicide events.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Risk; Schizophrenia; Suicide; Suicide, Attempted; Young Adult | 2010 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3 | 2011 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Middle Aged; Neutropenia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia | 2011 |
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunohistochemistry; Locomotion; Male; Nerve Tissue Proteins; Neurons; Nucleus Accumbens; Piperazines; Proto-Oncogene Proteins c-fos; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2011 |
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Aripiprazole; Asian People; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine | 2010 |
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
Aripiprazole-induced pathological gambling: a report of 3 cases.
Topics: Adolescent; Aripiprazole; Gambling; Humans; Male; Piperazines; Quinolones; Schizophrenia; Young Adult | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipation; Enema; Fecal Impaction; Female; Gastrointestinal Agents; Humans; Lactulose; Male; Middle Aged; Piperazines; Polyethylene Glycols; Prevalence; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2011 |
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Long-Term Care; Male; Methamphetamine; Motor Activity; Piperazines; Psychoses, Substance-Induced; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2012 |
Placental transfer of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Maternal-Fetal Exchange; Piperazines; Pregnancy; Quinolones; Schizophrenia | 2011 |
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Linear Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Behavior; Treatment Outcome; Young Adult | 2011 |
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride | 2011 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2011 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Calculating occupancy when one does not have baseline: a comparison of different options.
Topics: Adult; Alkaloids; Antipsychotic Agents; Aripiprazole; Humans; Male; Methods; Piperazines; Positron-Emission Tomography; Protein Binding; Quinolones; Receptors, Dopamine D2; Reproducibility of Results; Schizophrenia; Young Adult | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Perinatal use of aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Fetal Blood; Humans; Maternal-Fetal Exchange; Milk, Human; Piperazines; Postnatal Care; Pregnancy; Prenatal Care; Quinolones; Schizophrenia | 2011 |
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
High dosage of aripiprazole-induced dysphagia.
Topics: Antipsychotic Agents; Aripiprazole; Deglutition Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2012 |
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden | 2011 |
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Hallucinations; Humans; Loxapine; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2011 |
Aripiprazole-related body-weight gain and nutritional counseling.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2011 |
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.
Topics: Adolescent; Adult; Aripiprazole; Asian People; Benzodiazepines; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Young Adult | 2011 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden | 2011 |
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia | 2011 |
Aripiprazole induced transient myopia: a case report and review of literature.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Myopia; Piperazines; Quinolones; Schizophrenia | 2012 |
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome | 2012 |
Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Behavior, Animal; Brain; Comet Assay; Humans; Lipid Peroxidation; Male; Mice; Micronucleus Tests; Mutagens; Piperazines; Quinolones; Schizophrenia | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2011 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological | 2011 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2011 |
Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Rhabdomyolysis; Schizophrenia; Taiwan | 2011 |
Manic induction with interferon alpha therapy.
Topics: Adult; Antipsychotic Agents; Antiviral Agents; Aripiprazole; Bipolar Disorder; Hepatitis C; Humans; Interferon-alpha; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Intermittent aripiprazole for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2012 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Aripiprazole may be free from tachyphylaxis: preliminary findings.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachyphylaxis; Treatment Outcome | 2012 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoxetine; Immune System; Male; Motor Activity; Piperazines; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2012 |
Tardive laryngeal dystonia associated with aripiprazole monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Laryngeal Diseases; Movement Disorders; Piperazines; Quinolones; Schizophrenia; Young Adult | 2012 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Quinolones; Retreatment; Risperidone; Schizophrenia; Sex Hormone-Binding Globulin; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sulpiride; Testosterone | 2012 |
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interactions; Female; Haloperidol; Humans; Hyperhidrosis; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2012 |
The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome; Young Adult | 2012 |
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Dibenzothiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quetiapine Fumarate; Quinolones; Review Literature as Topic; Risperidone; Schizophrenia; Sulpiride | 2012 |
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2012 |
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzodiazepines; Dibenzothiazepines; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Reaction Time; Receptor, Adenosine A2A; Risperidone; Schizophrenia; Sensory Gating; Up-Regulation | 2012 |
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Humans; Male; Medication Adherence; Patient Discharge; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2012 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
[Dysphagia or dysphagias during neuroleptic medication?].
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Clonazepam; Deglutition Disorders; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Homicide; Humans; Ill-Housed Persons; Loxapine; Male; Mental Disorders; Piperazines; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology | 2012 |
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Diagnostic and Statistical Manual of Mental Disorders; DNA; Drug Interactions; Female; Genotype; Humans; Japan; Luminescence; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Postmenopause; Prolactin; Quinolones; Receptors, Dopamine D2; Regression Analysis; Schizophrenia; Sex Characteristics | 2012 |
Daily dose of 105 mg aripiprazole because of delusional origin: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Drug Overdose; Female; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Self Medication | 2012 |
Aripiprazole augmentation for clozapine-associated tardive torticollis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia; Torticollis; Treatment Outcome | 2012 |
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studies; Cerebral Cortex; Drug Partial Agonism; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Positron-Emission Tomography; Pyridines; Quinolones; Radiopharmaceuticals; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2013 |
Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brain; Cognition; Electroencephalography; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2013 |
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents | 2013 |
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult | 2013 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult | 2013 |
Torsades de pointes after administration of low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Complications; Drug Monitoring; Heart Arrest; Humans; Hypertension; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Stroke; Torsades de Pointes; Treatment Outcome | 2013 |
Aripiprazole (Abilify) for schizophrenia.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Dopamine Agonists; Drug Interactions; Fees, Pharmaceutical; Humans; Intestinal Absorption; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Therapeutic Equivalency | 2003 |
Aripiprazole. The newest antipsychotic agent for treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole.
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Humans; Patents as Topic; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole and extrapyramidal symptoms.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Biological Availability; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States | 2003 |
Medication developments in the treatment of mental illness.
Topics: Adolescent; Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Blood Glucose; Child; Depressive Disorder; Humans; Mental Disorders; Piperazines; Primary Health Care; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2003 |
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
Topics: Anger; Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia | 2004 |
Aripirazole-olanzapine combination for treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Anxiety; Aripiprazole; Dopamine Antagonists; Humans; Nicotinic Agonists; Piperazines; Psychotropic Drugs; Quinolones; Receptors, Metabotropic Glutamate; Receptors, Nicotinic; Schizophrenia | 2003 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Aripiprazole: novelty, adherence and understatement.
Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Therapeutic Equivalency | 2005 |
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2004 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2004 |
[Expectation and development of atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2004 |
Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Down-Regulation; Humans; Models, Neurological; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia; Treatment Outcome | 2004 |
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2004 |
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid | 2005 |
Partial agonists in schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Up-Regulation | 2005 |
Aripiprazole in schizophrenia: consensus guidelines.
Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
[Combining effectiveness and tolerance].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Female; Humans; Long-Term Care; Patient Compliance; Physician-Patient Relations; Piperazines; Prognosis; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
An African patient with ziprasidone intolerance.
Topics: Africa; Antipsychotic Agents; Aripiprazole; Dystonia; Ethnicity; Germany; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome | 2005 |
[Aripiprazole in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Reversal of symptomatic hyperprolactinemia by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2005 |
8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity.
Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia | 2005 |
['Awakening': a confusing improvement during treatment with atypical antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Humans; Piperazines; Quality of Life; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2005 |
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Spectrophotometry, Ultraviolet | 2005 |
Diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Female; Humans; Infusions, Intravenous; Insulin; Insulin, Isophane; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Second generation antipsychotics--aripiprazole revisited.
Topics: Antipsychotic Agents; Aripiprazole; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2005 |
Aripiprazole: new drug. Just another neuroleptic.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drugs, Investigational; Haloperidol; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
The patient with schizophrenia taking aripiprazole: case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Approval; Humans; Male; Outcome Assessment, Health Care; Patient Participation; Piperazines; Quality of Life; Quinolones; Schizophrenia | 2005 |
A case of Aripiprazole and extra pyramidal side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Aripiprazole as a dopamine partial agonist: positive and negative effects.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists | 2006 |
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome | 2007 |
[No rebound psychosis in a case of switching from clozapine to quetiapine].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Humans; Limbic System; Mesencephalon; Neural Pathways; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2006 |
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2006 |
Three cases of risperidone-induced enuresis.
Topics: Aripiprazole; Enuresis; Female; Humans; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2006 |
Clozapine augmentation with aripiprazole for negative symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome | 2006 |
High-dose aripiprazole in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole and the neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2006 |
Elevated lipase and diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
[Pharmacology of antipsychotic drugs]].
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Norepinephrine; Piperazines; Quinolones; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology | 2006 |
Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia.
Topics: Acoustic Stimulation; Animals; Brain Chemistry; Cyclic GMP; D-Amino-Acid Oxidase; Disease Models, Animal; Dose-Response Relationship, Radiation; Excitatory Amino Acid Antagonists; Extremities; Female; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Motor Activity; Neural Inhibition; Neurologic Examination; Phencyclidine; Psychomotor Performance; Quinolones; Reaction Time; Reflex, Startle; Schizophrenia; Sex Factors; Swimming | 2006 |
Aripiprazole-associated seizure.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Schizophrenia; Seizures | 2006 |
A case of dose-dependent aripiprazole-induced conduction disturbance.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bundle-Branch Block; Dose-Response Relationship, Drug; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2006 |
Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure | 2007 |
Aripiprazole in chronic schizophrenia: experiences in daily practice.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2006 |
Atypical neuroleptic malignant syndrome associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2006 |
Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
[Endocrine side effects among psychiatric patients treated with antipsychotics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; Endocrine System; Female; Galactorrhea; Gynecomastia; Humans; Male; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Schizophrenia; Sulpiride | 2006 |
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection | 2007 |
Urinary obstruction with citalopram and aripiprazole combination in an elderly patient.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Citalopram; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Urinary Retention | 2006 |
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.
Topics: Adult; Aripiprazole; Clozapine; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Italy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Retrospective Studies; Schizophrenia; Treatment Outcome | 2006 |
Diagnostic and therapeutic challenges in narcolepsy-related psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2006 |
Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient.
Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Humans; Middle Aged; Mutation; Piperazines; Quinolones; Schizophrenia | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia | 2007 |
Aripiprazole-associated acute dystonia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Drug Interactions; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline | 2007 |
Indexing of reports on aripiprazole augmentation of clozapine.
Topics: Abstracting and Indexing; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Information Services; Information Storage and Retrieval; Piperazines; Quinolones; Schizophrenia | 2007 |
Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Weight Loss | 2007 |
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia | 2007 |
Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Male; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia | 2007 |
Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Lamotrigine; Piperazines; Quinolones; Schizophrenia; Stevens-Johnson Syndrome; Triazines | 2007 |
Intramuscular aripiprazole in the control of agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; United Kingdom | 2007 |
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles | 2008 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Diabetic Ketoacidosis; Humans; Male; Olanzapine; Pancreatitis; Piperazines; Quinolones; Schizophrenia | 2007 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission | 2007 |
Combined use of ECT with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Electroconvulsive Therapy; Hospitalization; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2009 |
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2008 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Remission Induction; Schizophrenia; Substance-Related Disorders | 2007 |
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia | 2007 |
A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Time Factors | 2007 |
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Aripiprazole and perphenazine: no difference.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Marketing; Perphenazine; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires | 2007 |
A case of aripiprazole-related tardive akathisia and its treatment with ropinirole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Indoles; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2007 |
Tardive dystonic symptoms associated with aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Humans; Intellectual Disability; Male; Ocular Motility Disorders; Piperazines; Quinolones; Schizophrenia | 2008 |
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride | 2008 |
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2007 |
Aripiprazole treatment for risperidone-associated tic movement: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schizophrenia; Tic Disorders | 2008 |
Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Movement Disorders; Piperazines; Quinolones; Schizophrenia | 2008 |
Aripiprazole diminishes cannabis use in schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Piperazines; Quinolones; Schizophrenia | 2008 |
Partial agonists and suicide: the role of the mental health nurse.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Nurse's Role; Piperazines; Quinolones; Schizophrenia; Suicide Prevention | 2008 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia | 2009 |
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Use of Aripiprazole in treatment resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2008 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia | 2008 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Prescriptions; Drug Therapy, Combination; Female; Hospital Bed Capacity, 300 to 499; Hospitals, Psychiatric; Hospitals, University; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Schizophrenia | 2008 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Piperazines; Quinolones; Schizophrenia | 2008 |
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding Sites; Brain; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2008 |
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding, Competitive; Brain; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Pituitary Gland; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult | 2008 |
Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2009 |
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome | 2008 |
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benztropine; Corpus Striatum; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2008 |
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2001 |
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Brain; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Neurons; Piperazines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Tomography, Emission-Computed | 2002 |
The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
Topics: Adult; Dopamine Agents; Hallucinations; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology | 1988 |